Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and SCAN domain-containing protein 9 (ZSCAN9) is a sequence-specific DNA-binding transcription factor predicted to regulate transcription by RNA polymerase II[1][2]. It contains a C2H2-type zinc finger domain, which enables DNA binding, and a SCAN domain that mediates homodimer and selective heterodimer formation with other SCAN domain-containing transcription factors, influencing the transcriptional activity and regulatory networks of gene expression[3]. While the ZSCAN family is recognized for roles in cell differentiation, proliferation, and cancer biology, specific biological functions or disease associations for ZSCAN9 remain largely uncharacterized[2][3]. ZSCAN9 is primarily localized to the nucleus[2].
Not applicable; no known drugs target ZSCAN9 directly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and SCAN domain-containing protein 9 (ZSCAN9).